September 15, 2022 7:56am

Another economic data day, think caution

Indications: 1 Positive Indication, 5 Negative Indications and 1 Pump/Promotes

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

More frequently right than consequentially wrong; there is VALUE out there. What I provide is an intelligence daily.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.04% or (-11 points), S&P futures are DOWN -0.20% ( -7 points) and NASDAQ futures are DOWN -0.40% (-48 points) early in the pre-open – so far,


U.S. equity futures were mixed waiting again for economic data,

European markets fluctuating yet a bit higher,

Asia pacific markets are mixed as Chinese indexes dip.



Indexes, the Dow and S&P and the Nasdaq rose slightly in choppy trading on Wednesday as investors tried to find their footing after the biggest one-day drop in more than two years.

The Dow closed UP +30.12 points (+0.10%) the S&P closed UP +13.32 points (+0.34%) while the Nasdaq closed UP +84.10 points (+0.74%)

A key factoid, “The stock market's roughly 24% decline this year, on a peak-to-trough basis, is broadly in line with past mild U.S. recessions, according to this Oxford Economics chart.” <MarketWatch>
Economic Data Docket: retail sales, import prices and jobless claims, as well as the Philadelphia Fed manufacturing survey and the Empire State manufacturing survey – all at 8:30 a.m. ET.


RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: catches a full breath after a deep dive in choppy waters. A market and sector reflex moves to the upside as I had written, “Which companies are still bleeding, changing places to the upside, responding to news flow, looking for opportunity or getting further burned?” …


Ebb and flow:

Q3/22 – September – 1 holiday, 6 positive and 3 negative closes

•             August – 1 neutral, 11 positive and 11 negative closes

•             July - 1 holiday, 10 negative and 10 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indications:

BioLife Solutions (BLFS) closed up +$0.26 to $26.11 after Tuesday’s -$0.65, Monday’s -$0.12, Friday’s -$0.08 after last Thursday’s +$1.34 with a negative -$0.53 or -2.03% pre-open indication,

Intellia Therapeutics (NTLA) closed up +$0.73 to $63.88 with a negative -$1.22 or -1.91% pre-open indication,

Ionis Pharmaceuticals (IONS) closed up +$1.16 to $47.41 with a negative -$0.25 or +-0.53 pre-open indication

uniQure NV (QURE) closed up +$0.96 to $21.15 after Tuesday’s -$0.34, Monday’s +$0.03 with a negative -$0.85 or +4.02% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$4.64 to $72.19 after Tuesday’s +$2.86, Friday’s +$0.69 and last Thursday’s +$1.26 with a negative -$1.44 or -1.99% pre-open indication,


Positive Indication:

Vericel (VCEL) closed up +$0.72 to $25.76 with a positive +$1.16 or +4.50% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$0.15 with 2,101 shares traded after Tuesday’s -$0.30 with 500 shares traded, Monday’s -$0.10 with 442 shares traded, Friday’s +$0.06 with 3,600 shares traded, and last Thursday’s +$0.59 with 3,900 shares traded, <3-month average = 1,746>,

  • How many non-citizens of Chinese nationality are employed at BSTG – 3 managers/directors of 5 and 3 of 5 board directors?
  • Who and WHAT are funding the “spikes” in volume and share price?
  • What is DST Capital?  Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG?  Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
  • WHY do I ask?
  • Are Chinese communist bureaucrats from Beijing, China directing the company’s activities?


The BOTTOM LINE: The cell and gene therapy sector rally got a bounce Wednesday, but it's barely a blip after the “our” universe with 32 on my 35-coverage list dived to some of last year’s depths!

I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!

A supporting quote, “Inflation is really a dark cloud over equities, but I think it’s really important that people keep in mind that it’s not about good and bad in the markets, it’s about better and worse,” he added, “and it does appear that inflation is getting better.” <CNBC>

Cell and gene therapy might be rebounding after Tuesday deep dive considering coming off a lousy earnings season which is about be yet another Q3 ends September 30 (Friday) – today is the 15 of September

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash? Start by looking at cell and gene therapy companies trading below cash!” 

Second Question, “How many companies are LOSING the investment high ground? TOO MANY” …!!!

Investors need to come to terms of the cell and gene therapy sector’s state of affairs and health as individual company’s actions cast doubts upon sentiment as reflected by August’s final accounting of positive and negative closes.

·         August – 1 neutral, 11 positive and 11 negative closes

September, so far has …

·         1 holiday, 5 positive and 3 negative closes

Companies NEED BETTER outreach to investors which means … NOT to enrich themselves at shareholder’s expense!

CEO salaries, spending the G&A are totally OUT-OF-WHACK; these are companies are in the development stage and will be for years without products in most cases not like the tech companies, who CEOs and management teams think they should be compared to for bi-weekly cash and “beanies”!

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

Also, investors can’t afford the outsized valuation price targets by I-Banks research and believe that CEOs are “accomplices” to over-estimating expectation and guidance in regard to valuation

The only thing investors are able to hang to at that point is HOPE – which is not a technical or fundamental indicator.  Keep your eyes on historical pricings that, haven’t responded to I-Bank research price targets.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”

That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.